Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy

Equality Impact Assessment (Guidance development) (PDF 144 KB)

Register of interests (PDF 114 KB)

Final draft guidance: (2) TA713

Final appraisal document (PDF 231 KB)

Committee papers (PDF 144 KB)

Appeal

BMS ltd : Appeal letter (MSWord 110 KB)

BMS Ltd : Scrutiny letter (MSWord 58 KB)

BMS Ltd : Response to scrutiny letter (MSWord 86 KB)

BMS Ltd : Final scrutiny letter (MSWord 56 KB)

Final draft guidance: (1) TA713

Final appraisal document (PDF 254 KB)

Committee papers (PDF 3.1 MB)

Public committee slides (PDF 905 KB)

Final scope (PDF 200 KB)

Final stakeholder list (PDF 242 KB)

Final scope - reissued May 2021 (PDF 207 KB)

Final appraisal document - TA484 (PDF 584 KB)

Final appraisal document Managed Access Agreement - TA484 (PDF 675 KB)

Committee papers - TA484 (PDF 4.58 MB)

Public committee slides - TA484 (PDF 601 KB)

Appraisal consultation document (PDF version) - TA484 (PDF 373 KB)

Committee papers - TA484 (PDF 2.19 MB)

Public committee slides June 2016 - TA484 (PDF 317 KB)

Public committee slides August 2016 - TA484 (PDF 518 KB)

Appraisal consultation document (PDF version) - TA484 (PDF 326 KB)

Committee papers - TA484 (PDF 13.06 MB)

Public committee slides - TA484 (PDF 1.19 MB)

Final scope - TA484 (PDF 141 KB)

Final stakeholder list - TA484 (PDF 220 KB)

NICE's response to comments on the draft scope and provisional stakeholder list - TA484 (PDF 301 KB)

Equality impact assessment (Scoping) - TA484 (PDF 63 KB)

Draft scope pre referral - TA484 (PDF 144 KB)

Draft matrix pre referral - TA484 (PDF 177 KB)